Ranking Profile - Adicet Bio Inc

Introduction

Adicet Bio Inc (Adicet Bio), formerly resTORbio Inc, is a biotechnology company. The company is engaged in developing allogeneic gamma delta T cell therapies for addressing the unmet medical need of solid tumors and hematological cancers. Adicet Bio's pre-clinical pipeline includes ADI-001, a CD20 CAR-T cell therapy candidate for the treatment of non-hodgkin's lymphoma; and ADI-002, a GPC3-targeting chimeric antigen receptor (CAR) for the treatment of hepatocellular carcinoma. It is also advancing the ADI-00x program for multiple solid tumors. Adicet Bio utilizes its proprietary immune cell platform that engineers gamma delta T cells with CARs and T cell receptors to generate T cell receptor-like monoclonal antibodies (TCRLs) directed to intracellular proteome to kill tumor cells. The company works in collaboration with Regeneron Pharmaceuticals Inc to develop engineered immune-cell therapeutics for cancer. It operates in the US. Adicet Bio is headquartered in Boston, Massachusetts, the US.